IOF Positions and Statements

Una revisión bibliográfica llevada a cabo por el Grupo de Trabajo sobre Inflamación Crónica y Estructura Ósea (CIBS) de la Fundación Internacional de Osteoporosis (IOF) concluyó que el tratamiento temprano y agresivo de la AR con agentes biológicos, particularmente, aquellos anti-reumáticos que modifiquen biológicamente la enfermedad (DMARDs), podría ser más efectivo para la detención de la... Read more
Below is a Statement issued by IOF to the BMJ in response to: Clinical assessment and management of multimorbidity: summary of NICE guidance. Farmer et al, BMJ 2016; 354: i4843 Read more
Recent research has shown that bone health is compromised in people with diabetes, resulting in a significantly higher risk of fragility fracture. Read more
The FRAX Fracture Risk Assessment Tool is a resource developed for the calculation of an individual’s 10-year probability of hip fracture and a major osteoporotic fracture based on specific clinical risk factors, with or without bone mineral density (BMD) values. Read more
A myth which often re-surfaces in media reports is that milk may not be beneficial to bone health. Bone health experts are concerned that this may be causing confusion among the general public and causing many people to avoid milk and dairy foods unnecessarily – when in fact they are among the best sources of bone-healthy nutrients. Read more
A new review published by a joint scientific working group of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the International Osteoporosis Foundation (IOF) finds that current evidence continues to support the potential for bone turnover markers (BTMs) to provide clinically useful information for monitoring osteoporosis treatment.1 The IFCC-IOF Working Group... Read more
The newly revised consensus statement serves to update and expand the areas of consensus following the publication of the Global Consensus on Menopausal Hormone Therapy (MHT) by leading global menopause societies in 2013. At the time, the Global Consensus succeeded in presenting guidelines that have been helpful to both healthcare providers and potential users of MHT. Read more
In people with osteoporosis, one fracture often leads to more fractures, and potentially a future of pain, disability, and poor quality of life. While studies have shown that such high-risk patients benefit from appropriate medication to reduce future fracture risk, more research is needed on the effect of osteoporosis medications on fracture healing.  Read more
senior and doctor checking ankle bandage
Una fractura en las personas con osteoporosis, a menudo, conduce a más fracturas. Los estudios han demostrado que estos pacientes de alto riesgo se benefician de los medicamentos apropiados para reducir el riesgo de fracturas futuras, sin embargo, se necesita más investigación sobre el efecto de los medicamentos para la osteoporosis en la consolidación de fracturas Read more
patient sits with doctor
A new editorial published by an International Osteoporosis Foundation (IOF) Working Group urges physicians to individualize treatment decisions based on their patient’s fracture risk, rather than automatically interrupting or stopping bisphosphonate therapy after five or three years. Read more

Pages

Subscribe to IOF Positions and Statements